Everyone from cable owners/operators, consortium members, technology providers, innovators, consultants, service partners, government entities, financiers, surveying companies – the whole industry – will be onsite at the true ‘one-stop shop’ for any susbea cable project.
“Subsea infrastructure underpins how the world lives and works, making this gathering critical for the industry’s future. For 2025, we’ve brought together an outstanding line-up of leaders to share their insights, while the exhibition floor will showcase solutions designed to drive progress. We’re thrilled to welcome the global subsea community back to Singapore for what will be the largest edition yet,” said Paul Clark, Managing Director (Asia), Terrapinn.
This year’s event features more than 70 sponsors, exhibitors, and partners, including Title Sponsor Nokia, Platinum Sponsor Ciena, and Gold Sponsors ASN, Digital Realty, HMN Tech, Mobily, center3, Huawei and Telecom Egypt.
Attendees will hear from 130 influential speakers from every inhabited continent around the world. Both mornings begin with the daily Keynote sessions and then following are six specialist theatres, with three running each day. Choose from: Defence, Cable, Data Centres & CLS, Strategy, Network and O&M.
Keynote Speakers Include:
Abdullah A. Alghonaimi, VP Wholesale Operations, Mobily
Rayan Alsaedi, Senior Advisor, Digital Infrastructure and Communication Deputyship, MCIT (Kingdom of Saudi Arabia)
Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (the “Company” or “Doubleview”) is pleased to announce important and very significant assay results from its 2025 drilling program at the Hat Polymetallic Deposit in northwestern British Columbia. The results from drill holes H090, H091, and H092 include some of the most substantial intervals of high-grade copper and gold mineralization encountered at the Hat Project to date and expand the footprint of mineralization well beyond the area considered in the maiden Mineral Resource Estimate that was reported in a 25/07/2024 news release. Drill holes H090, H091, and H092 provide more details of the East Lisle Zone, and shallow extension of the Main Lisle Zone.
Partial Data from 2025 Drill Holes:
The recent drilling focused on the core Lisle Zone, where drilling intercepted what is interpreted as a potential porphyry feeder zone. The intercepts demonstrate both shallow and deep mineralization horizons and provide further evidence of the Hat Deposit’s robust mineralization profile.
Table 1 summarizes important assay intervals from drill holes H090, H091 and H092. [Note that scandium (Sc) values are excluded from copper equivalent estimates but are shown to ensure complete disclosure of relevant data]. Data from subsequent drill holes will be released when assays are received and have been verified. To date (11/09/2025) 12 drill holes have been completed with total 8,506 metres (27,906 feet) and work is continuing.
Table 1: Summary of Significant % CuEq Drill Core Intercepts
DDH
From (m)
To (m)
Length (m)
CuEq (%) Excl. Sc2O3
Ag (g/t)
Au (g/t)
Co (g/t)
Cu (%)
Sc (g/t)
H090
33.0
274.8
241.8
0.15
0.22
0.06
50
0.08
27
H090
Including
194.0
262.0
68.0
0.30
0.42
0.13
64
0.17
27
H090
Including
194.0
210.6
16.6
0.76
1.04
0.40
62
0.42
24
H090
Including
194.0
231.0
37.0
0.44
0.61
0.21
66
0.24
27
H091
18.0
49.0
31.0
0.15
0.21
0.07
74
0.06
34
H091
153.0
231.0
78.0
0.28
0.54
0.22
47
0.09
29
H091
Including
153.0
180.0
27.0
0.58
1.16
0.56
64
0.13
28
H091
Including
154.8
156.0
1.2
5.26
7.16
6.43
230
0.37
19
H092
51.0
717.0
666.0
0.45
0.36
0.23
75
0.24
28
H092
Including
51.0
75.0
24.0
0.69
0.59
0.61
109
0.18
28
H092
Including
54.0
63.0
9.0
1.22
0.9
1.18
174
0.26
24
H092
Including
305.5
717.0
411.5
0.62
0.48
0.3
86
0.35
30
H092
Including
380.0
717.0
337.0
0.73
0.56
0.36
95
0.42
30
H092
Including
497.0
717.0
220.0
0.87
0.71
0.46
75
0.49
30
H092
Including
497.0
697.0
200.0
0.88
0.74
0.46
77
0.50
30
H092
Including
497.0
666.0
169.0
1.00
0.83
0.53
84
0.56
30
Notes:
1 – Copper Equivalent (CuEq) currently does not include the Scandium
2 – The intervals presented in this table are not true widths. The true width of mineralized sections has not been determined.
3 – Metal equivalents should not be relied upon for future evaluations. – Drill hole intercepts included in this news release are core lengths that may or may not be true widths of mineralization. It is not possible to determine true widths. –
4 – Parameters used to calculate Copper Equivalent: Au price (US$/oz): 1900; Ag price (US$/oz): 24; Cu price (US$/lb): 4; Co price (US$/lb): 22. Au recovery: 89.0%; Ag recovery: 68.0%; Cu recovery: 84.0%; Co recovery: 78.0%. * Copper Equivalent Calculation CuEq in % = ([Ag grade in ppm] *24*0.68/31.1035 + [Au grade in ppm] *1900*.89/31.1035 + 0.0001* [Co grade in ppm] *22*0.78*22.0462 + 0.0001* [Cu grade in ppm] *4*0.84*22.0462)/(4*22.0462*0.84).
Table 2 summarizes coordinates of the recent drill holes.
Table 2. Details of Location and direction of drill holes:
DDH ID
UTM- East (m)
UTM- North (m)
Elevation (m)
Azimuth (°)
Dip (°)
Max- Depth (m)
Year
H090
347703
6454749
1025
-65.12
90
501
2025
H091
347703
6454749
1025
-88.39
0
441
2025
H092
347963
6453927
966
-61.83
120
741
2025
Drill hole H090 shows a very long interval 241.8 metres (793.3 feet) of mineralization with 0.15% CuEq within which are 68 m of 0.30% Cu Eq that includes 16.6 m of 0.76% CuEq.
Drill hole H091 shows several intervals with elevated levels of %CuEq, of which 153m to 180 metres (27m/88.6 ft) carries 0.58% CuEq and a remarkable 5.26% CuEq over 1.2m [Please note that the latter is an obvious outlier with 0.37% Cu, 6.43 g/t Au, 7.16g/t Ag and 230 g/t Co].
Drill hole H092 also shows numerous long intervals of high %CuEq including some near surface and others at depth that illustrate the potential for locating one or more “feeder” zones to the main Lisle Zone.
The grades and intercepts reported from holes H090, H091 and H092 confirm the high-grade nature of the mineralization within parts of the Lisle Zone and may be indicative of proximity to the “core” and possible “feeder” zone. The intercepts display consistent copper, gold and strong cobalt values, as well as consistent scandium mineralization, further reinforcing the Hat Deposit’s potential as a significant resource of strategic metals.
Figures 1 and 2 illustrate in plan and sectional views the recent drill holes H090 and H091 along with a conceptual open pit outline. The conceptual pit likely will be adjusted substantially as more data becomes available.
Figure 3 illustrates drill hole H092 and pre-existing drill holes. H092 is one of the most important drill holes on the Hat property because it greatly extends the zone of higher-grade mineralization easterly and to depth. Several subsequent drill holes were designed to confirm and explore this area.
Figure 1: Drill Plan with the Induced Polarization Plan and 2024 Conceptual Pit Outline
“We are very pleased to present initial assay data from our 2025 field season. Included in the data are several startlingly important features of high-grade mineralization and expanded dimensions. We look forward to their inclusion in an MRE and Preliminary Economic Assessment (PEA) in progress. Meanwhile we await with considerable interest the receipt additional assay data.
We are also watching with great interest the steadily rising prices for our principal metals, copper, gold, silver and scandium, as the world markets react to this period of uncertainty, a new era of fractured trade relationships, global warming, inflation, and tariffs and the renewed emphasis on strategic metals. The recently announced possible merger of Teck Corporation with Anglo-American illustrates the active consolidation within the mining industry as established members seek to increase and buffer their positions.
We believe that Doubleview will play an important role in Canada’s mining industry as we expand our resource and plan for a bright future.”
Quality Assurance and Quality Control:
Hat Project drill cores are processed at Doubleview’s camp where they are photographed, measured and logged by our technical staff and then divided using a diamond bladed saw. One half is placed in a stout bag to form the assay sample that is forwarded securely to the independent analytical lab. The remaining half core is stored on site where it is available for further examination and sampling. The assay cores are subject to a Chain of Custody routine as they are shipped from camp to a bonded carrier for delivery to the lab.
Core samples are analysed at the North Vancouver facility of ALS Canada Ltd. using their PREP-31, PGM-ICP24, ME-MS61, and ME-ICP06 packages. Each core sample is dried, then crushed to 70% passing a 2mm screen. All material is processed in an automatic Riffle splitter to yield a 250g homogenized, representative sample. This sub-sample is then pulverized to 85% passing a 75-micron screen. All samples are analyzed for Au, Pt, Pd by 50g fire-assay fusion/ICP-ES finish, using PGM-ICP24 package. A separate 0.25g pulp split is analyzed by Four Acid digestion/ICP-MS finish, reporting 48 elements. Over limit elements are analyzed by Ore Grade Four Acid digestion/ICP-ES finish using ME-OG62 assay package. All of Doubleview’s core samples are analyzed or assayed at independent ISO 17025 and ISO 9001- certified laboratories.
When initial assays are received and accepted by our staff, a certain fraction of the samples will be sent to a second ISO-certified lab for check assay and verification purposes. Assays will be reported in News Releases.
Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview’s Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the technical contents of this news release. He is not independent of Doubleview as he is a shareholder in the company.
About Doubleview Gold Corp
A mineral resource exploration and development company is headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX-Venture Exchange (TSXV: DBG) (OTCQB: DBLVF) (WKN: LA1W038)(FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals-utilizing cutting-edge exploration techniques.
Doubleview’s success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company’s strategic initiatives. Doubleview looks forward to further collaborative growth and development, and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.
About the Hat Polymetallic Deposit
The Hat Deposit, located in northwestern British Columbia, is a polymetallic porphyry project with major resources of copper, gold, cobalt, and the potential for scandium. As one of the region’s significant sources of critical minerals, the Hat deposit has undergone targeted exploration and development. The 0.2% CuEq cut-off resource estimate, as of the recently completed Mineral Resource Estimate and the Company’s July 25, 2024, news release, is summarized below:
Average Grade
Metal Content
Open Pit Model Hat
Resource Category
Tonnage
CuEq
Cu
Co
Au
Ag
CuEq
Cu
Co
Au
Ag
Mt
%
%
%
g/t
g/t
million lb
million lb
million lb
thousand oz
thousand oz
In Pit
Indicated
150
0.408
0.221
0.008
0.19
0.42
1,353
733
28
929
2,045
Inferred
477
0.344
0.185
0.009
0.15
0.49
3,619
1,945
91
2,328
7,575
Scandium potential for the Hat Deposit is estimated to be 300 to 500 million tonnes at an average grade of 40 ppm (0.004%) Sc2O3.
For further details of the MRE, please refer to the Company’s July 25, 2024 news release.
On behalf of the Board of Directors,
Farshad Shirvani, President & Chief Executive Officer
For further information please contact:
Doubleview Gold Corp Vancouver, BC Farshad Shirvani President & CEO
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Certain of the statements made and information contained herein may constitute “forward-looking information.” In particular references to the private placement and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.
Spritzer Bhd (“Spritzer” or the “Company”), Malaysia’s leading natural mineral water brand, today embarked on a fresh and exciting new chapter in the beloved brand’s journey and efforts to deepen their connection with consumers across the nation with the launch of a two-part mini-drama in September and November 2025. The mini-drama series stars acclaimed actress and Spritzer’s new Brand Ambassador, Anna Jobling, in emotionally relatable roles, facing real-life conflict, dilemmas and personal growth.
Shiao Chan, Head of Marketing of Spritzer, said, “Beyond providing engaging storylines and entertainment, these dramas are works of arts that subtly embed Spritzer Sparkling’s values of healthy lifestyles, wellness and community, to resonate with our Malaysian consumers and audience across different ages. Through the characters, their emotions, and visual storytelling, we hope to convey and navigate this complex narrative of familial values and the virtues of self-care, whilst embedding the encouragement for Malaysians to shift toward healthier habits and beverage choices.”
Figures 1 and 2: Spritzer connects with Malaysians to inspire health and wellness through two mini-drama series with latest brand ambassador, Anna Jobling.
`
Figure 3: Anna Jobling, Spritzer’s latest brand ambassador
The collaboration also marks the beginning of a new chapter with Anna Jobling stepping into the role of a Spritzer Brand Ambassador. Known for her elegant and grounded persona, Anna embodies the essence of Spritzer’s clean and natural brand philosophy. Her authenticity and grace make her a fitting face for both Spritzer Natural Mineral Water and Spritzer Sparkling, products that reflect purity, wellness, and refreshment. Spritzer’s collaboration with Anna Jobling is more than a brand endorsement, it is a shared mission to champion wellness, authenticity, and sustainability.
Catch the two compelling dramas, each with three episodes, this September and November, at @Spritzerwater IG or Tik Tok respectively web link, Instagram or TikTok
Bukan Salahku explores themes of betrayal and self-worth, following Anna’s character who values family above all. As she faces duplicity from her own kin, she makes the right decision for herself over familial expectations. Apa Harga Diriku? delves into the pressures of fame and materialism, culminating in a journey of self-discovery and empowerment. Anna navigates difficult choices between fame, money and relationships, ultimately breaking free from the influence of others to embrace the best version of herself.
Spritzer’s foray into storytelling through the mini-drama series is a natural extension of its continuous commitment to connect with Malaysians through creative storytelling and purposeful content, where entertainment meets advocacy for healthier habits and lifestyles. Spritzer continues to champion wellness in relatable and motivating ways, sparking meaningful conversations around self-care and lifestyle choices among Malaysians.
With zero sugar and sweeteners, natural mineral water, and silica-rich content, Spritzer Sparkling offers a refreshing alternative to sugary carbonated drinks for daily consumption, a wellness-forward choice which is especially crucial in a country where diabetes rates remain among the highest in Southeast Asia. Through engaging content and meaningful experiences, Spritzer showcases its commitment to inspiring healthier choices amongst the nation. Spritzer is not just Malaysia’s leading natural mineral water brand; it is also a lifestyle partner for Malaysians seeking balance and vitality in their everyday lives.
Spritzer was also recognised as the Top Rising Brand in the Beverage Category in the recent Brand Footprint Malaysia 2025 by Kantar Worldpanel, a recognition of its growing resonance with Malaysian consumers as their preferred beverage. About Spritzer
Spritzer, Malaysia’s No.1 bottled water brand since 1989, sources its water from a 430-acre tropical rainforest in Taiping. The water undergoes a natural filtration process through underground rocks for over 15 years, enriching it with essential minerals like Silica, which benefits skin, bones, hair, and nails.
As a leader in smart manufacturing, we use advanced technology to ensure quality and safety. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to sustainability. Tested annually by SIRIM, our products are free from microplastics.
Spritzer offers a full range of products, from Natural Mineral Water and Sparkling Water to Distilled Water and Fruit-flavoured Beverages, catering to every lifestyle and occasion. With a vision to become a circular brand by 2030, we are committed to sustainability and delivering quality you can trust.
Spritzer—nature, innovation, and sustainability in every bottle. For more information, please visit www.spritzer.com.my.
For the third consecutive year, Karbon-X (OTCQX:KARX) and the Banff Half Marathon have partnered to take meaningful, measurable climate action that reflects the natural values of the Rockies.
This year’s race included verified climate contributions covering the event’s footprint, along with voluntary contributions made by runners at registration. By choosing an optional add-on at checkout, participants were able to make a personal impact, integrating climate action directly into their race experience.
The story behind this effort is as local as it is global. Banff has long lived in rhythm with nature, from the early hydro stations that powered mountain towns to campfires that bring people together after a day outdoors. The climate contributions made through this partnership echo that legacy, supporting clean energy and sustainable heat in communities worldwide, just as Banff has done for generations.
“Partnering with Karbon-X has given us a meaningful way to align our race with the values of the community” said Paul Regensburg, Race Director of the Banff Half Marathon. “Our runners care about protecting the places they love, and this partnership helps turn that care into action.”
“The Karbon-X collaboration with the Banff Half Marathon is built on a shared commitment to protecting the pristine environment that makes this race a world-class destination,” said Matt Kauffman, EVP of Sports & Entertainment at Karbon-X. “We’re proud to provide runners with a simple, effective way to balance their environmental impact. At its core, this partnership is about taking collective responsibility for our footprint, safeguarding the beauty of Banff, and advancing a shared vision for a sustainable future, helping competitors run for a purpose that is larger than the race itself.”
Through 2027, Karbon-X continues its role as the Banff Half Marathon’s Sustainability Partner, working together to minimize impact and inspire collective action among participants and the broader community.
To learn more about this year’s contributions and impact, visit: www.karbon-x.com/banff-marathon-2026
About Karbon-X
Karbon-X Corp. (OTCQX: KARX) is a vertically integrated climate solutions company delivering end-to-end climate solutions across both compliance and voluntary markets. From project origination and emissions quantification to third-party verification, credit issuance, and market distribution, Karbon-X ensures transparency and impact at every step. Karbon-X makes trusted climate action accessible not only to businesses and institutions, but also to individuals and everyday people who want their choices to create lasting impact.
The Banff Half Marathon is Canada’s most breathtaking running experience, welcoming thousands of runners each June to one of the world’s most iconic landscapes. With a growing commitment to sustainability, the event celebrates personal achievement and environmental stewardship in equal measures.
The World Quantum Summit (WQS) 2025 returns to Singapore from 23–25 September at Sheraton Towers, Singapore, under the theme “Quantum Unboxed: Extending the Reach of AI.” As the premier global forum focused on pragmatic quantum deployments, this year’s Summit spotlights how quantum technologies are actively transforming industries—from logistics and finance to healthcare and security.
Quantum Capital Index™️ 2025
WQS unveils its flagship Quantum Capital Index™️ (QCI) 2025, a 45-page strategic benchmark analyzing 60 global quantum startups. With $2 billion+ in funding tracked, QCI ranks the top 30 companies across key metrics such as financial scale, technological readiness, market adoption, and capital efficiency to provide actionable intelligence for investors and enterprise leaders (wqs.events).
Pre-Summit Workshops – 23–24 September
Ahead of the main conference, participants will join an immersive two-day workshop series led by the Singapore University of Technology and Design (SUTD).
These sessions are designed to equip delegates with the fundamental knowledge of quantum technology—covering core concepts in quantum computing, communication, and security—ensuring all attendees are well-prepared to engage with the technical depth and real-world applications presented during the summit.
The workshops will combine lectures, demonstrations, and hands-on training, giving participants:
A grounding in quantum mechanics principles relevant to computing.
Exposure to quantum programming basics and simulation tools.
Insights into quantum communication and cryptography foundations.
Context for how these fundamentals translate into the industry deployments showcased at WQS.
All participants will receive a Certificate of Completion awarded by SUTD, providing formal recognition of their achievement and readiness to engage in advanced quantum dialogue.
Conference Highlights – 25 September
Delegates will then dive into cutting-edge sessions addressing the most pressing developments in quantum and AI convergence:
Global Quantum Investment Landscape – latest funding flows, deal trends, and the unveiling of the Quantum Capital Index™️.
Frontiers in Quantum Hardware – superconducting, photonic, ion-trap, and hybrid architectures.
Quantum Security & Cryptography – readiness of quantum-safe encryption, VPNs, and standards.
Quantum in Finance – case studies in fraud detection, portfolio optimization, and market risk modeling.
Quantum for Healthcare & Pharma – breakthroughs in drug discovery and molecular simulation.
AI Meets Quantum – solving barren plateaus, debugging quantum ML, and scaling hybrid quantum–AI systems.
National Quantum Strategies – policy frameworks and East–West collaboration opportunities.
Building the Talent Pipeline – addressing the global skills gap in quantum-AI and cybersecurity.
Why This Summit Matters
Witness the convergence of AI and quantum in action—no hypotheticals, just delivered results.
Dive deep with the QCI report: understand where capital, technology, and market readiness intersect.
Hands-on demos, certifications, curated investor-founder forums, and East-West thought leadership converge to shape the next phase of quantum disruption.
Register & Learn MoreFor full agenda, registration details, and insights, visit wqs.events about the event and QCI 2025.
Media Contact: Eric Khoo (Mr.) Head of Global Events and Partnerships The Pinnacle Group International eric.khoo@pinnaclegroup.global +65 8383 2480
– Demonstrating Remarkable Resilience Amid a Challenging Macroeconomic Environment
CBL International Limited (NASDAQ: BANL) (the Company or CBL), the listing vehicle of the Banle Group (Banle or the Group), a leading marine fuel logistics company in the Asia-Pacific region, has announced its unaudited financial results for the six months ended June 30, 2025 on September 2, 2025.
1H 2025 Financial and Operational Highlights – Revenue of $265.17million, reflecting resilient performance in a volatile macro environment. – Sales volume increased by 9.8%, driven by network expansion, new customer acquisitions, and expansion toward the non-container liner and biofuel segments. – Gross profit margin increased to 1.02% in 1H2025, reflecting the Company’s strategic approach to maintaining profitability while growing market share in a competitive environment. – Net loss narrowed by 38.8% year-on-year to $992,000, demonstrating improved cost control and operating efficiency. – Biofuel sales surged 154.7%, driven by accelerating adoption of sustainable marine fuels under IMO 2023 and EU FuelEU Maritime regulations. – Global network expanded to 65 ports, strengthening CBL’s role as a global one-stop marine fuel logistics platform. – Cash balance of $5.43 million and $50 million committed banking facilities provide strong financial flexibility to support growth and shareholder value.
Financial Performance Overview The Company reported consolidated revenue of $265.17 million for the six months ended June 30, 2025, representing a 4.4% decrease from $277.23 million in the same period of 2024. The decrease was mainly attributable to the decrease in the marine fuel price which was partially offset by the increase in the sales volume. The increase in sales volume was mainly driven by network expansion, new customer acquisitions, and expansion toward the non-container liner and biofuel segments. Furthermore, the Group’s network demonstrated the Group’s resilience to geopolitical impacts on the marine industry.
Gross profit remained stable at $2.71 million with an increase in sales volume to cope with the challenging competition in the market, while gross profit margin increased from 0.98% in 1H2024 to 1.02% in 1H2025. This margin expansion reflects the Company’s strategic approach to maintaining profitability while growing market share in a competitive environment.
The Company reported a net loss of $992,000 for the six months ended June 30, 2025, representing a significant 38.8% improvement compared to a net loss of $1.62 million in the same period of 2024, primarily driven by disciplined cost management and operational efficiency initiatives that reduced operating expenses by 17% to $3.42 million from $4.12 million in 1H 2024.
Cash and cash equivalents stood at $5.43 million as of June 30, 2025, supported by improved working capital management and expanded banking facilities of $50.0 million, providing enhanced financial flexibility for growth initiatives.
Strategic Expansion and Operational Excellence CBL’s operational expansion continued to be a key growth driver, with the Company’s global service network reaching 65 ports by June 30, 2025, strategically positioned across Asia Pacific, Europe, Africa, and Central America. This expansion enabled CBL to effectively navigate geopolitical disruptions, particularly in the Red Sea region and the Middle East, along with the changes in global trade patterns due to the impact of U.S. tariffs policy, by capturing increased demand along alternative intra-Asia and Euro-Asia trade routes.
Customer diversification reached a significant milestone, with non-container liner sales accounting for 36.9% of revenue, while sales concentration among the top five customers declined to 60.4% from 66.7% in 1H 2024. The Company continues to service nine of the world’s top 12 container shipping lines, which contributed nearly 60% of global container fleet capacity.
Additionally, biofuel sales demand was fueled by stricter environmental regulations, including IMO’s Carbon Intensity Indicator and the EU’s FuelEU Maritime, and surged 154.7% year-on-year in 1H2025, with volumes up 189.5%, reinforcing CBL’s forerunning position in sustainable marine fuels. The Company stayed ahead of this trend with the successful rollout of its B24 biofuel in China, Hong Kong, and Malaysia, followed by a 2025 launch in Singapore. The B24 blend, comprising 76% conventional fuel and 24% UCOME, delivers a 20% reduction in greenhouse gas emissions compared to traditional marine fuels.
Stricter Environmental Regulations and Industry Reshaping Despite the unpredictability of U.S. trade policy, oil prices, and geopolitical risks, CBL remains cautiously optimistic about the outlook as further uncertainties could impact our results of operations for a particular period. Regarding the ongoing instability in the Red Sea, where vessels were rerouted via the Cape of Good Hope, CBL targeted the increased demand from rerouted vessels, ensuring that our strategic supply chain could meet these demands, allowing us to maintain the stability of our offerings and capitalize on the opportunities created by these disruptions.
The adoption of biofuels and other sustainable marine fuels is accelerating as stricter environmental regulations reshape the shipping industry. Consultant agency Exactitude Consultancy is projecting a 50.4% CAGR for the green marine fuel market from 2023 to 2030, as demand for biofuels is expected to climb sharply. Leveraging its early move into sustainable fuels, CBL is expanding its biofuel supply chain and exploring LNG and methanol, positioning itself to capture growth while helping customers meet tightening decarbonization targets across Asia Pacific, Europe, and other key markets.
Management Commentary and Future Outlook
Dr. Teck Lim Chia, Chairman and CEO of CBL International Limited, stated, “Our first half results highlight significant strategic progress. Despite a challenging macro backdrop, we successfully expanded our global network, accelerated our biofuel transition with triple-digit growth, and narrowed our net loss by nearly 40%. These achievements underscore our resilience, operational discipline, and confidence in long-term growth.
As regulations tighten and customer demand for sustainable marine fuels accelerates, CBL is uniquely positioned as an early mover with the ISCC certifications and supply partnerships to lead the market transition. We remain focused on executing our strategy to deliver profitable growth and long-term shareholder value.”
Outlook Looking ahead, CBL expects to: – Further scale its biofuel supply chain and explore LNG and methanol, leveraging regulatory support and customer adoption. – Continue expanding port coverage to enhance global connectivity. – Maintain disciplined cost management and capitalize on financial flexibility to invest in sustainable fuels and potential shareholder return initiatives.
Webcast Details CBL International Limited (Nasdaq: BANL) cordially invites you to participate in a webcast to discuss its financial results for the six months ended June 30, 2025.
Event:
2025 Interim Results Webcast
Date and Time:
10:00 pm – 11:00 pm US EST on September 15, 2025 (Monday)
10:00 am – 11:00 am MST/HKT on September 16, 2025 (Tuesday)
CBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.
Forward-Looking Statements Certain statements in this announcement are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” “should,” “would,” “plan,” “future,” “outlook,” “potential,” “project” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. They involve known and unknown risks and uncertainties and are based on various assumptions, whether or not identified in this press release and on current expectations of BANL’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of BANL. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, fuel prices and tariffs, market, financial, political and legal conditions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.
CBL INTERNATIONAL LIMITED (Incorporated in the Cayman Islands with limited liabilities)
Company leverages dual-market strategy and technology-driven standardization to strengthen its leadership in China’s TCM sector and enter international markets.
Sichuan Neautus Traditional Chinese Medicine Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange. The IPO is intended to raise capital to support the company’s expansion both domestically and internationally amid rapid modernization of China’s traditional Chinese medicine (TCM) industry.
Founded in 2021, Chengdu, China, Neautus has grown into a leading player in the herbal decoction pieces market, with annual revenue exceeding RMB 1.2 billion.
Dual Growth Engines Neautus operates a “dual-engine” growth model, balancing institutional sales and consumer demand.
The company supplies more than 1,000 major hospitals in China and is continuing to grow. And through its B2B platform, “Jinfang Caotang,” which is an online platform aimed at meeting the demands of approximately 90,000 TCM clinics in China, the company has seen significant success. Since the launch of “Jinfang Caotang,” the platform has attracted over 5,200 registered TCM clinics within a year, signaling high growth.
In the consumer market, Neautus specializes in ready-to-consume herbal supplements aimed at a diverse demographic of Traditional Chinese Medicine (TCM) users in China. Additionally, the company has expanded its reach into overseas markets, including Hong Kong, Taiwan, Vietnam, and Malaysia.
Technology-Driven Standardization Neautus is the first company worldwide to apply DNA barcoding technology to identify herbal materials, a standard recognized by both the Chinese and British Pharmacopoeias. This achievement earned the company the National Science and Technology Progress Award (Second Class). In recent years, Neautus has also obtained a series of high-level certifications—from “Chengdu Digital Workshop” to Sichuan Province’s “Advanced Smart Factory”—highlighting its advancement toward Intelligentization 2.0.
Market Tailwinds and Global Expansion Supported by national policies promoting standardization, Frost & Sullivan projects China’s TCM market will exceed RMB 599.3 billion by 2030. IPO proceeds will fund overseas capacity, international certifications, cross-border e-commerce, regional acquisitions, and entry into European and U.S. markets. The company is also planning on developing AI-assisted diagnostic tools via its “Jinfang Cloud” platform.
IPO Outlook The IPO underscores Sichuan Neautus’s role in transforming the TCM industry from traditional manufacturing to value-driven healthcare innovation, while further strengthening its position as an industry leader and advancing the sector toward higher standards and quality.
About Sichuan Neautus Traditional Chinese Medicine Co., Ltd. Sichuan Neautus Traditional Chinese Medicine Co., Ltd. specializes in high-quality herbal decoction pieces and health supplements, combining technology, traceability, and research to serve domestic and international markets.
On August 29, SERES announced its 2025 mid-year results, reporting strong growth across all key metrics. In the first half of the year, SERES achieved operating revenue of CNY 62.4 billion and net profit attributable to shareholders of CNY 2.94 billion—an 81% year-on-year increase. R&D investment reached CNY 5.12 billion, up nearly 155% from the prior year, while NEV sales totaled 172,108 units.
This impressive performance was fueled by robust demand for premium smart electric vehicles under the AITO brand, supported by exceptional product quality and delivery capabilities. Contributing factors include the versatile MF Platform for efficient model development, the Super Factory for rapid production scaling, advanced digital-intelligent quality assurance systems, and a modern luxury experience that continues to strengthen AITO’s market reputation.
AITO’s latest models continue to raise the bar, with the AITO 9 and AITO 8 maintaining their positions as sales leaders.
In the first half of this year, the AITO series continued to evolve with several new launches, including the AITO 5 Ultra, the 2025 Edition AITO 9, and the AITO 8—all of which received strong market and consumer response.
Thanks to improvements across its entire value chain, AITO has set new standards for delivery among China’s luxury new energy vehicle brands. As of August 2025, total deliveries of all AITO models have surpassed 750,000 units. Notably, cumulative deliveries of the AITO 9 have exceeded 220,000 units, making it the top-selling vehicle in the CNY 500,000 luxury car segment. The AITO 8 quickly became a bestseller after its debut, with over 70,000 units delivered and holding the top spot in the CNY 400,000 price segment for four consecutive months.
Additionally, according to LandRoads’ Brand Health Tracking Study for New Energy Vehicles in the first half of 2025, the AITO brand ranked No. 1 in the Brand Development Confidence Index. The AITO 9 also led the overall new energy vehicle Net Promoter Score (NPS) rankings, with a score of 85.2.
Notably, AITO launched an all-electric version of its family-focused flagship SUV, the AITO 8, on August 25. The all-new AITO 7 is also set to make its official debut in September. With the ongoing introduction of new models, AITO continues to expand its product lineup to meet the diverse needs of consumers and strengthen its leadership in the luxury new energy vehicle market.
A Commitment to Technological Innovation and Robust R&D Investment Technological innovation is central to SERES’ long-term growth. The company has consistently invested in research and development, driving new advancements and achieving remarkable results in technology. In the first half of 2025, SERES invested CNY 5.20 billion in R&D—nearly a 155% increase year-over-year. The number of R&D personnel reached 6,984, up approximately 27% from last year and now comprising 36% of the company’s total workforce.
At this year’s Shanghai Auto Show, SERES unveiled its intelligent safety system, pioneering a scenario-based approach to vehicle safety. The new system establishes an intelligent safety framework across four key areas: life protection, vehicle body protection, health care, and privacy protection. This comprehensive approach ensures user safety throughout the entire vehicle lifecycle and sets a new industry benchmark for intelligent safety.
Previously, SERES introduced a series of major technological advancements, including the SERES MF Platform, SERES Super Range-Extender, and the SERES Super Factory. The SERES Super Factory has been an industry pioneer with its “factory-within-a-factory” model, driving product integration, intelligent manufacturing, and industrial clustering to boost collaboration and innovation. The company also set a new industry standard with its Zero-Carbon Smart Logistics Hub.
Brand Value Surges Amid Strong Investor Confidence As the world’s fourth new energy vehicle manufacturer to achieve profitability, SERES laid a strong foundation for growth in the first half of the year through strategic product portfolio optimization, technological innovation, and enhanced operational efficiency.
SERES also ranked 169th on the 2025 Fortune China 500 list. This was an ascent of 235 spots from the previous year, making it the fastest-climbing company on the list. On the TopBrand 2025 China’s Top 500 Brands list, released in August, SERES ranked 92nd with a brand value of CNY 175.52 billion, breaking into the automotive industry’s top 10 and highlighting its leadership in brand development and market influence. More recently, on August 28, SERES climbed to 59th place—up 174 spots—on the 2025 China Top 500 Private Enterprises list, becoming the top-ranked private enterprise in Chongqing.
Meanwhile, the capital markets continue to show strong confidence in SERES’ future growth. In the past six months, nearly 40 securities firms have issued “Buy” ratings for SERES, with expectations that the company will maintain a strong growth trajectory throughout the second half of the year.
On August 29, Yuzhou Group Holdings Company Limited (HKG: 1628) announced that its offshore debt management and restructuring efforts, which spanned over three years, have yielded decisive results. The offshore restructuring has officially taken effect, marking a key step in improving the Company’s liquidity and optimizing its financial structure, laying a solid foundation for future robust operations.
Optimize Capital Structure, Enhance Financial Stability and Achieve Sustainable Development After multiple rounds of negotiations, the final arrangement encompassed 15 senior notes, one perpetual bond, four secured notes, one syndicated loan, and one bilateral loan. As consideration for the restructuring, Yuzhou Group issued new bonds with an optimized structure, including short-term, medium-term, and long-term bonds. This arrangement significantly reduced financing costs, lowered the Group’s outstanding offshore debt, alleviated financial pressure, optimized its capital structure, and enhanced financial soundness and sustainability.
Gain Support from Shareholders and the Market, Consolidate the Interests of all Parties, and Work Together to Move Forward As a key component of the plan, certain creditors will receive 5,645 million newly issued shares, representing approximately 37.94% of Yuzhou Group’s issued shares after the restructuring. This further solidified the shared interests of creditors and the Company. In addition, Yuzhou Group raised nearly HK$100 million through a rights issue to cover restructuring-related expenses and replenish working capital. The arrangement not only set a market precedent but also garnered a positive response from minority shareholders, reflecting strong recognition and confidence from shareholders and the market in both the rationale of the plan and the Group’s future development prospects.
The core objective of this restructuring plan was to adjust the scale of Yuzhou Group’s offshore debt to a reasonable level, restore the soundness and sustainability of the capital structure, and ensure the continued operation and healthy development of the business. At the same time, the plan aims to ease liquidity pressure, align the new repayment schedule with the operating environment of China’s real estate industry and the Group, and ensure the fair treatment and protection of all stakeholders’ rights, striving to maximize overall value.
Respond to Policy Calls, Fulfill Social Responsibilities, and Consolidate Corporate Value Following the completion of the restructuring, Yuzhou Group will continue to respond to policy initiatives, fulfill its commitment to “guaranteeing housing delivery”, strengthen cash flow management, enhance internal revenue generation capabilities, and ensure stable business operations. Structural deleveraging measures are expected to help the Group achieve a long-term sustainable capital structure and reduce overall operational risks. The Company will steadily enhance its operating capacity and remain focused on creating value for all stakeholders.
Industry observers note that the completion of the restructuring not only relieves near-term financial pressure but also represents an important step for Yuzhou Group in pursuing long-term stability and growth amid the ongoing adjustment of China’s real estate sector.
On August 29, Everest Medicines(HKG: 1952) announced its interim results for the six months ended June 30, 2025. The Company’s total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. Non-IFRS loss narrowed by 31%, and gross margin excluding non-cash items was 76.4%. As of the end of June, the Company maintained a solid cash balance of RMB 1.6 billion. Additionally, with the successful completion of a share placement on August 1, which generated net proceeds of HK$1.553 billion, Everest’s total cash position increased further, providing a strong foundation for commercialization expansion and R&D investment. Supported by the excellent performance of its core products, Everest remains confident in achieving its full-year revenue guidance of RMB 1.6 to 1.8 billion and expects to turn operating cash flow positive in Q4.
BOCOM International released its latest report today, noting that the strong sales performance of Everest Medicines’ Nefecon(R) far exceeded expectations. The institution significantly raised its revenue forecasts for 2026–2027 and lifted its target price to HK$84. The report highlighted a rich pipeline of catalysts from the second half of 2025 through 2026, including the approval, commercialization, and reimbursement negotiations of etrasimod in China, as well as potential BD opportunities for the Company’s proprietary pipeline. BOCOM International believes the current valuation remains attractive and reiterated its “Buy” rating.
“In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical company by deepening our ‘dual-engine’ strategy. We have built a commercialization platform anchored by two blockbusters covering high-potential markets and powered by the in-house discovery and clinical translation of in vivo CAR-T and mRNA therapeutic cancer vaccine platforms.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.
Core Products Deliver Strong Growth, Driving Commercial Platform Momentum NEFECON(R), the blockbuster product in the renal portfolio, delivered particularly strong performance. As the first and only fully approved etiological treatment for IgA nephropathy (IgAN) in China, the United States, and Europe, NEFECON(R) generated revenue of RMB 303 million in the first half of 2025, representing 81% year-over-year growth. However, our first half revenue was artificially low due to a supply constraint that was rooted in both strong market demand and a delay in regulatory approval of a supplemental application for production scale up designed to ensure supply stability. This has been fully resolved since our supplemental application was approved by the China CDE on Aug 1, 2025. Following the supplemental application was approved by the China CDE in August, supply capacity increased significantly. Cumulative sales from January to August reached RMB 825 million, including RMB 520 million in August alone, reflecting strong market demand. Full-year sales are expected to reach RMB 1.2–1.4 billion, with continued strong growth projected in 2026, potentially reaching RMB 2.4–2.6 billion.
Another Core product XERAVA(R), As the world’s first fluorocycline antibiotic recorded RMB 143 million in the first half of 2025, up 6% year-over-year. In-hospital sales increased 37% year-over-year, driven by Everest’s core hospital strategy.
Additionally, VELSIPITY(R) (etrasimod), a best-in-disease therapy for moderately to severely active ulcerative colitis (UC), is positioned as Everest’s next growth engine, with its NDA in mainland China expected to be approved in the first half of 2026. The localized production project for VELSIPITY(R) was officially launched at the Jiashan manufacturing site in March 2025, providing strong support for its future commercialization.
Global Proprietary Pipeline Value Emerging，Strong Prospects for Blockbuster Potential Everest continues to focus on achieving key breakthroughs in its proprietary pipeline, while accelerating the clinical development and global expansion of innovative assets with global rights. EVER001 (civorebrutinib), the next-generation covalent reversible BTK inhibitor, has delivered encouraging Phase 1b/2a clinical data in primary membranous nephropathy (pMN). With potential applications in IgAN, minimal change disease (MCD), and FSGS, covering a patient population of more than 10 million worldwide, EVER001 represents a significant market opportunity, with projected global peak sales exceeding RMB 10 billion. A global Phase II basket trial is expected to be initiated in the first half of 2026.
Leveraging its industry-leading mRNA therapeutic cancer vaccine platform and in vivo CAR-T platform, the Company is building a globally competitive R&D pipeline. EVM18, the in vivo CAR-T program, has completed multiple non-human primate (NHP) trials and achieved preclinical proof-of-concept, with first-in-human data expected by the end of 2025. EVM16, the personalized therapeutic mRNA cancer vaccine, has initiated its first-in-human trial in China, with patient dosing completed. In the investigator-initiated trial (IIT), dose escalation in the low- and mid-dose cohorts has been completed, with encouraging preliminary data observed. EVM14, an off-the-shelf tumor-associated antigen (TAA) vaccine, has received IND approval from the U.S. FDA and acceptance from China’s NMPA. The Phase I trial in the U.S. is currently underway, with first patient enrollment expected by September 2025. EVM15, the immune-modulatory cancer vaccine, has completed preclinical proof-of-concept and identified its clinical candidate.
Strategic Repositioning to Bolster Global Competitiveness During the reporting period, the Hong Kong Stock Exchange approved the removal of the “B” marker from Everest’s stock short name, reflecting recognition of the Company’s strong R&D pipeline, commercialization capabilities, and overall business fundamentals. In addition to the successful top-up placement, Everest invested approximately US$30.9 million in I-Mab (Nasdaq: IMAB) in August 2025. Following the transaction, Everest increased its ownership in I-Mab to approximately 16.1%, becoming its single largest shareholder, further strengthening its global presence in next-generation immuno-oncology therapies.
Analysts noted that Everest’s “dual-engine” strategy is rapidly delivering results. On the one hand, the Company’s powerful commercial platform—anchored by NEFECON(R) and VELSIPITY(R) and supported by XERAVA(R), Cefepime-taniborbactam, EVER001, and other high-potential assets—is expected to generate synergies with total peak sales exceeding RMB 25 billion globally. On the other hand, Everest’s in vivo CAR-T and mRNA therapeutic cancer vaccine platforms provide significant long-term growth potential through global development and partnership opportunities.
` 
